VolitionRX Limited (NYSEAMERICAN:VNRX) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of VolitionRX Limited (NYSEAMERICAN:VNRX) have earned an average rating of “Moderate Buy” from the five research firms that are presently covering the stock, MarketBeat.com reports. Three research analysts have rated the stock with a hold recommendation, one has issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among analysts that have covered the stock in the last year is $2.3333.

A number of brokerages have weighed in on VNRX. D. Boral Capital reaffirmed a “hold” rating on shares of VolitionRX in a report on Monday. Citigroup downgraded VolitionRX to a “hold” rating in a report on Monday. Finally, HC Wainwright reduced their target price on VolitionRX from $1.50 to $1.00 and set a “buy” rating on the stock in a report on Thursday, April 2nd.

Institutional Investors Weigh In On VolitionRX

A number of large investors have recently modified their holdings of the business. Virtu Financial LLC acquired a new stake in shares of VolitionRX in the 3rd quarter valued at $28,000. Northwestern Mutual Wealth Management Co. bought a new position in shares of VolitionRX in the 2nd quarter valued at $52,000. Geode Capital Management LLC lifted its stake in shares of VolitionRX by 9.8% in the 4th quarter. Geode Capital Management LLC now owns 963,986 shares of the medical research company’s stock valued at $246,000 after acquiring an additional 85,816 shares during the last quarter. Jane Street Group LLC bought a new position in shares of VolitionRX in the 4th quarter valued at $28,000. Finally, Squarepoint Ops LLC bought a new position in shares of VolitionRX in the 4th quarter valued at $34,000. Institutional investors and hedge funds own 8.09% of the company’s stock.

VolitionRX Price Performance

VNRX stock traded down $0.01 during midday trading on Monday, reaching $0.17. The company had a trading volume of 856,209 shares, compared to its average volume of 9,771,458. The company has a market capitalization of $26.47 million, a price-to-earnings ratio of -0.76 and a beta of 1.33. The stock has a 50 day moving average price of $0.20 and a 200-day moving average price of $0.29. VolitionRX has a 1-year low of $0.15 and a 1-year high of $0.94.

VolitionRX (NYSEAMERICAN:VNRX) last posted its quarterly earnings results on Tuesday, March 31st. The medical research company reported ($0.05) EPS for the quarter, meeting analysts’ consensus estimates of ($0.05). The company had revenue of $0.45 million during the quarter, compared to analyst estimates of $0.71 million. As a group, research analysts anticipate that VolitionRX will post -0.5 earnings per share for the current year.

About VolitionRX

VolitionRX, traded as VNRX on the NYSE American exchange, is a pioneering life sciences company focused on the development and commercialization of minimally invasive diagnostic tests for the early detection of cancer and other diseases. Utilizing proprietary technology to analyze circulating nucleosomes in blood samples, the company’s platform identifies disease-specific epigenetic and biochemical signatures. By offering blood-based screening solutions, VolitionRX aims to deliver alternatives to invasive, costly and time-consuming procedures, potentially improving patient outcomes through earlier diagnosis.

The company’s flagship product suite, branded as Nu.Q, comprises assays designed to detect biomarkers associated with a range of malignancies, including colorectal, lung and pancreatic cancers, as well as other systemic conditions.